CONNEXIN THERAPEUTICS LTD
Significant control: Connexin Therapeutics Group Ltd (75–100%)
From public filings as at 31 Aug 2026; may contain errors or be out of date. Verify at Companies House · Terms
Watch this company
Get an email when Companies House records a change for Connexin Therapeutics Ltd: status, filings, accounts, officers or owners. Free.
Not live yet: alerts start by 15 December 2026. We store your email and this company number only, for these alerts. If alerts don’t launch, we tell you and delete your address. Privacy
What does Connexin Therapeutics Ltd sell?
Registered activity: Research and experimental development on biotechnology (SIC 72110). We’re building product and service lists for UK companies. Get this one when it’s ready.
Summary
CONNEXIN THERAPEUTICS LTD is an active private limited company (company number 11503075) incorporated on 7 August 2018, registered in York. Its registered activity is research and experimental development on biotechnology (SIC 72110). Latest micro accounts cover the period ending 31 December 2024, showing net assets of £12k, with 0 employees on average. As micro-entity accounts, no profit and loss account is filed, so turnover and profit are not public. Net assets fell 11% on the prior period (£14k).
By net assets it sits in the upper half of 278 comparable companies in Other (median £129, upper quartile £59k).
Ownership and control
- Connexin Therapeutics Group Ltd
- owns 75–100% of shares
- Mr Carlos Velez
- owns 25–50% of shares
- holds 25–50% of voting rights
- Mr Stewart Bloomfield
- owns 25–50% of shares
- holds 25–50% of voting rights
Persons with significant control hold 25% or more of shares or voting rights. Smaller shareholdings are only listed in confirmation-statement documents. Directors and secretaries: see the officers list at Companies House.
Key dates
- Incorporated
- 7 August 20188 yrs ago
- Next accounts due
- 30 September 202627 days overdue
- Confirmation statement due
- 21 August 2027in 298 days
Due dates are expected from Companies House filing rules; confirm on the official register before relying on them.
Activity
- SIC 72110
- Research and experimental development on biotechnology
- Accounts type
- Micro Entity
- Size band
- MicroCompanies Act thresholds
Financials
| Period end | Net assets | Cash | Debtors | Creditors <1y | Turnover | Profit | Employees |
|---|---|---|---|---|---|---|---|
| 31 December 2024 | £12k | — | — | £1,100 | — | — | 0 |
| 31 December 2023 | £14k | — | — | £1,100 | — | — | 0 |
Figures as filed in iXBRL accounts at Companies House. "—" means the line was not reported in that filing; micro-entity accounts contain no profit and loss account.
Filing and accounts signals
- Net assets above zeroNet assets £12,080 at 31 December 2024
- Current assets at least 1.5× creditors within one yearCurrent ratio 11.98
- Incorporated five or more years agoIncorporated 7 August 2018
- Accounts past their due dateDue 30 September 2026
Neutral facts read from the register and filed accounts, each with its evidence. They are not a rating, a prediction or advice, and may be incomplete or out of date. How each signal is derived.
Timeline
- Confirmation statement duein 298 days
- Next accounts due27 days overdue
- Accounts period endNet assets £12k · micro accounts
- Accounts period endNet assets £14k · micro accounts
- Incorporated
Similar companies in the UK
- IKAROVEC LIMITEDNorwich · inc. Aug 2018
- EMG RESEARCH LIMITEDScarborough · inc. Aug 2018
- ACYUTA LTDChesham · inc. Jul 2018
- ZETTA GENOMICS LIMITEDNorwich · inc. Jul 2018
- URTICA PLUS LTDDiss · inc. Jun 2018
- EUROPEAN SCIENTIFIC RESOURCES LTDWrexham · inc. Jun 2018
All companies incorporated on 7 August 2018 · in Aug 2018.
Reminders for CONNEXIN THERAPEUTICS LTD
Get an email before each filing deadline — accounts and confirmation statement — so nothing is late.